{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:59:14Z","timestamp":1777503554696,"version":"3.51.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ministry of Health, Welfare and Sport"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is ongoing debate about the possible protective effect of the bivalent human papillomavirus (2vHPV) vaccine, targeting oncogenic types HPV-16\/18, against anogenital warts (AGWs), commonly attributed to HPV-6\/11. We performed a retrospective registry-based open cohort study to assess the effect of 2vHPV vaccination on AGWs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We linked general practice (ie, primary care) data from women born between 1993 and 2002, who had been eligible for HPV vaccination in the Netherlands, to the Dutch national immunization registry on an individual level. Women were followed until their first AGW diagnosis or end of follow-up. Adjusted incidence rate ratios (aIRRs) were estimated using Poisson regression with vaccination status as a time-dependent exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We linked data of 96 468 women with a total of 328 019 years observation time and 613 AGW diagnoses (incidence: 1.87\/1000 person-years). At the end of follow-up, 61% were 2vHPV vaccinated (\u2265\u20091 dose) of whom 91% were fully vaccinated. The AGW incidence was lower among those with \u2265\u20091 dose vs 0 doses (aIRR, 0.75 [95% confidence interval {CI}, .64\u2013.88]). The effect of vaccination was stronger after full vaccination (aIRR, 0.72 [95% CI, .61\u2013.86]) and for women who were offered vaccination at 12\u201313 years of age (aIRR, 0.69 [95% CI, .51\u2013.93]) vs those at 13\u201316 years of age (aIRR, 0.77 [95% CI, .64\u2013.93]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This is the largest population-based study so far to examine the effect of 2vHPV vaccination on AGWs, with reliable individual information on AGW diagnoses and vaccination status. The results indicate that 2vHPV vaccination partially protects against AGWs, especially when administered in early adolescence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa582","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T19:09:52Z","timestamp":1589310592000},"page":"291-297","source":"Crossref","is-referenced-by-count":8,"title":["Partial Protective Effect of Bivalent Human Papillomavirus 16\/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-7373","authenticated-orcid":false,"given":"Petra J","family":"Woestenberg","sequence":"first","affiliation":[{"name":"Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands"},{"name":"Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra E","family":"Guevara Morel","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"Amsterdam Public Health Research Institute, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes A","family":"Bogaards","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands"},{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00ebtte","family":"Hooiveld","sequence":"additional","affiliation":[{"name":"Nivel, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa M","family":"Schurink-van \u2018t Klooster","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian J P A","family":"Hoebe","sequence":"additional","affiliation":[{"name":"Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, The Netherlands"},{"name":"Department of Sexual Health, Infectious Diseases and Environment, South Limburg Public Health Service, Heerlen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne A B","family":"van der Sande","sequence":"additional","affiliation":[{"name":"Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium"},{"name":"Julius Center, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit H B","family":"van Benthem","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,18]]},"reference":[{"key":"2021071519595415400_CIT0001","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jadohealth.2010.01.016","article-title":"Beyond cervical cancer: burden of other HPV-related cancers among men and women","volume":"46","author":"Chaturvedi","year":"2010","journal-title":"J Adolesc Health"},{"key":"2021071519595415400_CIT0002","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"key":"2021071519595415400_CIT0003","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/TCRM.S81825","article-title":"Recurrent respiratory papillomatosis: current and future perspectives","volume":"11","author":"Carifi","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"2021071519595415400_CIT0004","doi-asserted-by":"crossref","first-page":"S849","DOI":"10.1093\/cid\/civ813","article-title":"Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines","volume":"61","author":"Park","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021071519595415400_CIT0005","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"2021071519595415400_CIT0006","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0956462414526706","article-title":"Impact of genital warts on emotional and sexual well-being differs by gender","volume":"25","author":"Vriend","year":"2014","journal-title":"Int J STD AIDS"},{"key":"2021071519595415400_CIT0007","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1186\/1471-2458-13-1065","article-title":"Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK","volume":"13","author":"Dominiak-Felden","year":"2013","journal-title":"BMC Public Health"},{"key":"2021071519595415400_CIT0008","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2334-13-39","article-title":"Systematic review of the incidence and prevalence of genital warts","volume":"13","author":"Patel","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2021071519595415400_CIT0009","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"2021071519595415400_CIT0010","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1080\/14760584.2018.1547196","article-title":"Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention","volume":"17","author":"Qendri","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"2021071519595415400_CIT0011","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/infdis\/jit361","article-title":"Declining genital warts in young women in England associated with HPV 16\/18 vaccination: an ecological study","volume":"208","author":"Howell-Jones","year":"2013","journal-title":"J Infect Dis"},{"key":"2021071519595415400_CIT0012","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/sextrans-2018-053786","article-title":"Epidemiology of genital warts in the British population: implications for HPV vaccination programmes","volume":"95","author":"Sonnenberg","year":"2019","journal-title":"Sex Transm Infect"},{"key":"2021071519595415400_CIT0013","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1016\/j.vaccine.2015.09.071","article-title":"Impact of quadrivalent human papillomavirus vaccine in women at increased risk of genital warts burden: population-based cross-sectional survey of Czech women aged 16 to 40 years","volume":"33","author":"Petr\u00e1\u0161","year":"2015","journal-title":"Vaccine"},{"key":"2021071519595415400_CIT0014","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.vaccine.2017.04.080","article-title":"Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain","volume":"35","author":"Navarro-Illana","year":"2017","journal-title":"Vaccine"},{"key":"2021071519595415400_CIT0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jinf.2017.01.007","article-title":"No evidence for cross-protection of the HPV-16\/18 vaccine against HPV-6\/11 positivity in female STI clinic visitors","volume":"74","author":"Woestenberg","year":"2017","journal-title":"J Infect"},{"key":"2021071519595415400_CIT0016","volume-title":"Sexually tranmitted infections in the Netherlands in 2015","author":"Van den Broek","year":"2016"},{"key":"2021071519595415400_CIT0017","volume-title":"Zorg door de huisarts. Uit: Zorg door de huisarts\u2014Nivel Zorgregistraties Eerste Lijn: Jaarcijfers 2017 en trendcijfers 2011\u20132017. Verantwoording cijfers huisartsenzorg [in Dutch]","author":"Boersma-van Dam"},{"key":"2021071519595415400_CIT0018","doi-asserted-by":"crossref","DOI":"10.2807\/ese.17.17.20153-en","article-title":"Pr\u00e6ventis, the immunisation register of the Netherlands: a tool to evaluate the National Immunisation Programme","volume":"17","author":"van Lier","year":"2012","journal-title":"Euro Surveill"},{"key":"2021071519595415400_CIT0019","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12875-015-0281-2","article-title":"Comparison of STI-related consultations among ethnic groups in the Netherlands: an epidemiologic study using electronic records from general practices","volume":"16","author":"Woestenberg","year":"2015","journal-title":"BMC Fam Pract"},{"key":"2021071519595415400_CIT0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ijc.26362","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16\/18","volume":"131","author":"Szarewski","year":"2012","journal-title":"Int J Cancer"},{"key":"2021071519595415400_CIT0021","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/infdis\/jit360","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation","volume":"208","author":"Szarewski","year":"2013","journal-title":"J Infect Dis"},{"key":"2021071519595415400_CIT0022","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021071519595415400_CIT0023","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/infdis\/jiy067","article-title":"High effectiveness of the bivalent human papillomavirus (HPV) vaccine against incident and persistent HPV infections up to 6 years after vaccination in young Dutch women","volume":"217","author":"Donken","year":"2018","journal-title":"J Infect Dis"},{"key":"2021071519595415400_CIT0024","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.vaccine.2018.01.057","article-title":"Human papillomavirus vaccine effectiveness by number of doses: systematic review of data from national immunization programs","volume":"36","author":"Markowitz","year":"2018","journal-title":"Vaccine"},{"key":"2021071519595415400_CIT0025","doi-asserted-by":"crossref","first-page":"12870","DOI":"10.1002\/jcb.28557","article-title":"The interaction of high and low-risk human papillomavirus genotypes increases the risk of developing genital warts: a population-based cohort study","volume":"120","author":"Hasanzadeh","year":"2019","journal-title":"J Cell Biochem"},{"key":"2021071519595415400_CIT0026","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1086\/590560","article-title":"Human papillomavirus genotype distribution in external acuminata condylomata: a large French national study (EDiTH IV)","volume":"47","author":"Aubin","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021071519595415400_CIT0027","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/OLQ.0b013e31827aa9b3","article-title":"Human papillomavirus typing in reporting of condyloma","volume":"40","author":"Stureg\u00e5rd","year":"2013","journal-title":"Sex Transm Dis"},{"key":"2021071519595415400_CIT0028","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1086\/498164","article-title":"Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination","volume":"192","author":"Vandepapeliere","year":"2005","journal-title":"J Infect Dis"},{"key":"2021071519595415400_CIT0029","doi-asserted-by":"crossref","first-page":"e023897","DOI":"10.1136\/bmjopen-2018-023897","article-title":"Prevalence and distribution of HPV types in genital warts in Xi\u2019an, China: a prospective study","volume":"9","author":"Zhu","year":"2019","journal-title":"BMJ Open"},{"key":"2021071519595415400_CIT0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1586\/14760584.2016.1124763","article-title":"Human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases","volume":"15","author":"Skinner","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2021071519595415400_CIT0031","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/infdis\/jix582","article-title":"Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors","volume":"217","author":"Woestenberg","year":"2018","journal-title":"J Infect Dis"},{"key":"2021071519595415400_CIT0032","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/infdis\/jiz280","article-title":"Bivalent human papillomavirus (HPV) vaccine effectiveness correlates with phylogenetic distance from HPV vaccine types 16 and 18","volume":"220","author":"Bogaards","year":"2019","journal-title":"J Infect Dis"},{"key":"2021071519595415400_CIT0033","doi-asserted-by":"crossref","first-page":"101593","DOI":"10.1016\/j.canep.2019.101593","article-title":"Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg","volume":"63","author":"Latsuzbaia","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"2021071519595415400_CIT0034","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3201\/eid2201.150736","article-title":"Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009\u20132013","volume":"22","author":"Cameron","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2021071519595415400_CIT0035","doi-asserted-by":"crossref","first-page":"e0212927","DOI":"10.1371\/journal.pone.0212927","article-title":"Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females","volume":"14","author":"van der Weele","year":"2019","journal-title":"PLoS One"},{"key":"2021071519595415400_CIT0036","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.virol.2006.06.021","article-title":"Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles","volume":"353","author":"Pinto","year":"2006","journal-title":"Virology"},{"key":"2021071519595415400_CIT0037","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1086\/320190","article-title":"A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers","volume":"183","author":"Evans","year":"2001","journal-title":"J Infect Dis"},{"key":"2021071519595415400_CIT0038","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin Immunol"},{"key":"2021071519595415400_CIT0039","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/infdis\/jix272","article-title":"Health and economic impact of a tender-based, sex-neutral human papillomavirus 16\/18 vaccination program in the Netherlands","volume":"216","author":"Qendri","year":"2017","journal-title":"J Infect Dis"},{"key":"2021071519595415400_CIT0040","doi-asserted-by":"crossref","first-page":"d5775","DOI":"10.1136\/bmj.d5775","article-title":"Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model","volume":"343","author":"Jit","year":"2011","journal-title":"BMJ"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa582\/33515460\/ciaa582.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/2\/291\/39064742\/ciaa582.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/2\/291\/39064742\/ciaa582.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T20:01:05Z","timestamp":1626379265000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/2\/291\/5839810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,18]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,5,18]]},"published-print":{"date-parts":[[2021,7,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa582","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,15]]},"published":{"date-parts":[[2020,5,18]]}}}